Fig. 2From: Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expressionDisease-free survival (DFS) was significantly longer in patients with low, compared to high, PD-1 and PD-L1 expressions (p = 0.006, log-rank) (a) (p = 0.001, log-rank) (b). DFS did not differ significantly between patients with low vs high PD-L2 expression (p = 0.657, log-rank) (c)Back to article page